BeStock  
Stocks › Biotechnology › JBIO

Jade Biosciences JBIO

US equityMarket cap rank #3116Biotechnology
$15.31 +$0.25 (+1.66%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.31 0.00%
Open$15.00
Prev close$15.06
Day range$15.00 – $15.54
Volume1.02M
Market cap$1.06B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$39.64M-44.7% YoY
Net profit-$35.06M-39.2% YoY
Diluted EPS-$0.42+12.5% YoY
Free cash flow-$28.91M-30.3% YoY
Operating cash flow-$28.91M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-30.7MDec '24$-38.2MMar '25$-32.1MJun '25$-25.2MSep '25$-31.9MDec '25$-40.4MMar '26$-55.8MJun '26$-35.1MSep '26

Diluted EPS by quarter

-0.95Dec '24-1.18Mar '25-0.86Jun '25-0.48Sep '25-0.65Dec '25-0.57Mar '26-0.76Jun '26-0.42Sep '26

Free cash flow by quarter

$-15.8MDec '24$-18.8MMar '25$-20.3MJun '25$-22.2MSep '25$-33.7MDec '25$-24.1MMar '26$-43.7MJun '26$-28.9MSep '26

Profitability & balance sheet

Return on equity-51.4%
Return on assets-47.4%
Return on invested capital-53.9%
Current ratio16.03
Liabilities / assets6.4%
Cash & investments$475.71M
Total debt$594,000.00
Net cash (debt)$475.11M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 Q4 2025 ANNUAL
Net cash flow from investing -$42.30M -$97.63M -$8.47M -$98.16M -$247.01M
-Change in Other Current Liabilities -$30,000.00 -$30,000.00 -$29,000.00 -$28,000.00 $40,000.00
-Change in Payables and Accrued Expense -$651,000.00 $1.69M $3.93M -$274,000.00 $3.77M
-Change in Prepaid Assets $191,000.00 -$2.83M $5.44M -$10.20M -$11.97M
Change in Working Capital -$490,000.00 -$1.17M $9.34M -$10.54M -$8.20M
Other Non-Cash Items $27,000.00 $25,000.00 $26,000.00 $26,000.00 $21.67M
Depreciation & Depletion & Amortization $16,000.00 $9,000.00 $9,000.00 $9,000.00 $26,000.00
Net Income from Continuing Operations -$35.06M -$55.77M -$40.37M -$31.93M -$127.41M
Net cash flow from continuing operations -$28.91M -$43.66M -$24.08M -$33.65M -$94.69M
Operating Cash Flow -$28.91M -$43.66M -$24.08M -$33.65M -$94.69M
Net Cash Flow from Continuing Investing Activities -$42.30M -$97.63M -$8.47M -$98.16M -$247.01M
Net PPE Purchase and Sale $0.00 – – -$3,000.00 -$196,000.00
Beginning Cash Balance $107.25M $55.09M $88.44M $50.11M $69.39M
Free Cash Flow -$28.91M -$43.66M -$24.08M -$33.65M -$94.89M
Effect of Exchange Rate Changes -$5,000.00 -$70,000.00 -$7,000.00 -$17,000.00 -$21,000.00
Financing Cash Flow $44.36M $193.52M -$795,000.00 $170.16M $360.77M
Net Cash Flow from Continuing Financing Activities $44.36M $193.52M -$795,000.00 $170.16M $360.77M
Net Common Stock Issuance $44.00M – – -$1.34M $189.11M
Proceeds from Stock Option Exercised $360,000.00 $2.12M $45,000.00 $384,000.00 $384,000.00
Net Other Financing Charges $0.00 $0.00 -$840,000.00 $171.12M $171.27M
Ending Cash Balance $80.39M $107.25M $55.09M $88.44M $88.44M
Net Change in Cash -$26.86M $52.24M -$33.35M $38.35M $19.07M
Net Investment Purchase and Sale -$42.30M -$97.63M -$8.47M -$98.19M -$246.78M
-Change in Other Current Assets – $0.00 $0.00 – -$38,000.00
Net Other Investing Changes – – – $28,000.00 -$31,000.00
Net Issuance Payments Of Debt – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 Q4 2025 ANNUAL
-Short Term Investments $395.32M $353.96M $256.21M $247.72M $247.72M
Other Current Assets $9.86M $10.05M $7.22M $12.66M $12.66M
Total Non-Current Assets $830,000.00 $862,000.00 $916,000.00 $965,000.00 $965,000.00
Net PPE $761,000.00 $793,000.00 $847,000.00 $896,000.00 $896,000.00
-Gross PPE $761,000.00 $793,000.00 $847,000.00 $896,000.00 $896,000.00
Other Non-Current Assets $69,000.00 $69,000.00 $69,000.00 $69,000.00 $69,000.00
Total Liabilities $30.89M $32.20M $22.97M $17.26M $17.26M
Total Current Liabilities $30.29M $31.57M $22.29M $16.54M $16.54M
Payables $3.03M $6.58M $3.98M $2.15M $2.15M
-Accounts Payable $3.03M $6.58M $3.98M $2.15M $2.15M
Current Accrued Expenses $6.85M $11.30M $12.90M $11.07M $11.07M
-Cash and Cash Equivalents $80.39M $107.25M $55.09M $88.44M $88.44M
Cash and Cash Equivalents & Short-Term Investments $475.71M $461.21M $311.30M $336.16M $336.16M
Total Assets $486.39M $472.11M $319.43M $349.78M $349.78M
Total Current Assets $485.56M $471.25M $318.52M $348.82M $348.82M
Other Current Liabilities $9.64M $9.77M $2.67M – –
Total Non-Current Liabilities $594,000.00 $628,000.00 $679,000.00 $724,000.00 $724,000.00
Long Term Debt and Capital Lease Obligation $594,000.00 $628,000.00 $679,000.00 $724,000.00 $724,000.00
-Long Term Capital Lease Obligation $594,000.00 $628,000.00 $679,000.00 $724,000.00 $724,000.00
Total Equity $455.50M $439.92M $296.46M $332.52M $332.52M
Stockholders' Equity $455.50M $439.92M $296.46M $332.52M $332.52M
Capital Stock $9,000.00 $8,000.00 $7,000.00 $7,000.00 $7,000.00
-Common Stock $7,000.00 $6,000.00 $5,000.00 $5,000.00 $5,000.00
-Preferred Stock $2,000.00 $2,000.00 $2,000.00 $2,000.00 $2,000.00
Additional Paid-In Capital $763.14M $711.09M $511.55M $506.77M $506.77M
Retained Earnings -$305.58M -$270.52M -$214.76M -$174.39M -$174.39M
Gains/Losses Not Affecting Retained Earnings -$2.07M -$660,000.00 -$342,000.00 $129,000.00 $129,000.00
Convertible preferred securities – – – $0.00 $0.00

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Selling and Admin Expenses $8.82M $8.85M $7.39M $20.42M $6.44M
Operating Profit -$39.64M -$58.92M -$43.45M -$113.54M -$34.98M
Net Non-Operating Interest Income (Expense) $4.63M $3.23M $3.10M $7.78M $3.09M
Non-Operating Interest Income $4.63M $3.23M $3.10M $7.78M $3.09M
Other Income (Expense) -$34,000.00 -$62,000.00 -$9,000.00 -$21.59M $20,000.00
Other Non-Operating Income (Expenses) -$34,000.00 -$62,000.00 -$9,000.00 -$21.59M $20,000.00
Pretax Profit -$35.05M -$55.75M -$40.35M -$127.35M -$31.87M
Tax $10,000.00 $15,000.00 $16,000.00 $58,000.00 $58,000.00
Net Profit -$35.06M -$55.77M -$40.37M -$127.41M -$31.93M
Profit from Continuing Operations -$35.06M -$55.77M -$40.37M -$127.41M -$31.93M
Net Income to Parent Company -$35.06M -$55.77M -$40.37M -$127.41M -$31.93M
Net Income to Common Stockholders -$35.06M -$55.77M -$40.37M -$127.41M -$31.93M
Basic EPS -$0.42 -$0.76 -$0.57 -$3.19 -$0.65
Research & Development $30.82M $50.07M $36.05M $93.12M $28.54M
-General & Admin Expense $8.82M $8.85M $7.39M $20.42M $6.44M
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $39.64M $58.92M $43.45M $113.54M $34.98M
Diluted EPS -$0.42 -$0.76 -$0.57 -$3.19 -$0.65

Discussion

No comments yet — be the first to weigh in on JBIO.

Sign in to join the discussion.

Scroll to Top